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ABSTRACT

Background: Counterpulsation devices (CPD) require electrocardiogram (ECG)
lead implantation for timing device filling and ejection with the native heart. Nonimplantable leads limit the scope of CPD treatment to short-term therapy.
Standard transvenous/epicardial ECG leads increase the invasiveness of
therapy.

Methods: To overcome these limitations, subcutaneous ECG leads were tested
in chronic (n=6) and acute (n=5) bovine models. ECG waveforms from clinicalgrade

epicardial

(control)

leads

and

subcutaneous

(test)

leads

were

simultaneously recorded resulting in 830 data epochs (30-s each) for a total of
44,614 heart beats. Device triggering using R-wave detection was calculated for
each lead type and compared. Additionally, the hemodynamic benefits of CPD
with

aortic

cannulation

(n=5)

was

investigated

during

normal

and

pharmacologically-induced heart failure, hypertension, and hypotension test
conditions.

Results: The subcutaneous leads provided 98.9% positive predictive
value and 98.9% sensitivity compared to the epicardial ECG leads. Out of 40
subcutaneous leads implanted in chronic animals, lead migration (sensing-end
movement >0.5cm, n=1) and lead fracture (n=1) were observed in two leads but
did not adversely impact triggering efficacy due to lead redundancy. The CPD
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cannulated to the aorta showed diminished left ventricular (LV) external work, LV
end diastolic volume, and LV end systolic volume during 1:1 support compared to
baseline in pharmacologically induced heart failure (HF). The CPD also
augmented cardiac output, aortic mean pressure, aortic pulse pressure, and
mean coronary artery flow.

Conclusion: These findings demonstrate the efficacy of chronic, subcutaneous
ECG leads for CPD timing. The hemodynamic feasibility of the CPD cannulated
to the aorta is equivalent or better than subclavian artery cannulation because of
the proximity to the heart, which may increase the size of CPD patient population
for warranted cases.
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CHAPTER I - BACKGROUND

Heart Failure

Heart Failure (HF) is an incurable, progressive disease that afflicts
5,100,000 people in the United States with a 50% mortality rate within 5 years.
According to the Center for Disease Control and Prevention, HF costs the nation
$32 billion per year including the cost of medication, medical services, and
missed days of work for HF patients. The prevalence of heart failure continues to
rise worldwide (~1,000,000 new patients per year) as the causes for heart failure
such as obesity, coronary artery disease, and hypertension persist [5].

Currently, pharmacological agents including using beta blockers, diuretics,
and ACE inhibitors is the preferred treatment option for HF patients until HF
progresses to an extent that a more aggressive therapy such as heart
transplantation or mechanical assist device therapy is warranted. Even though
the US averaged $8,915 per person on health care in 2012, the favorable
outcomes for HF patients are low [6]. Muntwyler J, and colleagues reported one
year mortality rates were 7.1%, 15.0%, and 28.0% for NYHA Class II, III, and IV,
respectively [7]. Approximately 30% mortality was reported at two years post
diagnosis in the RALES trial [8]. To combat this poor prognosis, heart
transplantation has been used in conjunction with immunosuppressant drugs and
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is considered the best form of end-stage HF therapy for long-term survival.
However, the supply of donor hearts (~2,300/year in the US) remains relatively
low while the demand continuously rises [9, 10].

Due to the shortage of available donor organs, alternative therapies such as
mechanical circulatory support (MCS) device implantation are needed. This
clinical need has led to significant research and development of cardiac assist
devices for destination therapy (support until death) and bridge to transplant
therapy (support until organ transplantation is available). Currently, for every
donor heart successfully transplanted, approximately two MCS devices are
placed in HF patients. The average cost of left ventricular assist devices is
$67,085 [11], which limits the use of these devices in developing countries. In
order expand the patient population for MCS therapy, a significant reduction in
cost as well as risks associated with surgical implantation is required. Current
chronic MCS devices require invasive surgical procedures (thoracotomies or
sternotomies) and the use of Cardiopulmonary Bypass. These procedures
involve risks of infection and other post-operative complications such as stroke
and device thrombosis. Therefore, countries worldwide are slow to adopt MCS
therapy as a means of HF treatment [12].
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Intra-Aortic Balloon Pump

Moulopoulos, et al. developed a prototype of an Intra-Aortic Balloon Pump
(IABP) in 1962. This device paved the way for counterpulsation as a means of
MCS therapy that is cost-effective ($800) [13]. Worldwide, IABP is implanted in
over 160,000 patients per year and is effective in the treatment of cardiogenic
shock and acute heart failure [14, 15]. IABP is a balloon which is surgically
inserted into the descending aorta via access of the femoral artery using a
modified Seldinger’s technique. Counterpulsation therapy is attained by rapidly
inflating the IABP immediately after the dicrotic notch and quickly deflating the
balloon just prior to ventricular systole.

The rapid inflation of the balloon increases the aortic diastolic pressure
which improves end-organ perfusion and coronary perfusion (up to 100%) [1621]. IABP deflation prior to ventricular systole decreases the ejection pressure of
the native ventricle, reducing after-load and left ventricular external work (LVEW)
[16, 22, 23]. The LV peak systolic pressure is reduced by up to 15% and the LV
end diastolic pressure is reduced by approximately 30% [16, 19, 24]. Among
other benefits is an increase in cardiac output and stroke volume, a decrease in
heart rate, more efficient metabolic function, and improved end organ perfusion
and function [25, 26]. IABP implantation is less invasive and consequently has
fewer intra- and post-operative complications compared to ventricular assist
devices. It cannot be used for chronic therapy and disallows ambulatory care for
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patients receiving treatment. There is a critical clinical need to develop
counterpulsation therapy for chronic and ambulatory use [19, 20, 22, 23, 27].

Synchronous Counterpulsation Devices

A number of devices have been developed to provide chronic
counterpulsation including C-Pulse (Sunshine Medical, Eden Prairie MN),
CardioVAD (LVAD Technologies, Detroit MI), and Symphony (Abiomed Inc.,
Danvers, MA) [28]. The C-Pulse is a non-blood contacting cuff that is implanted
around the ascending aorta. The CardioVAD is a blood-contacting polyurethane
sac that replaces a portion of the descending aorta. Both of these devices require
the use of thoracotomies and cardiopulmonary bypass for implantation. Because
LVAD Technologies and Sunshine Medical removed the minimally invasive
quality of IABP when designing CardioPlus and Sunshine Heart, these devices
now compete against other invasive MCS devices and have not been widely
accepted clinically. However, Jeevanandam et al. have demonstrated the clinical
benefits of the CardioPlus device such as increased cardiac output and end
organ perfusion [28, 29]. Symphony is a 32 ml device that is implanted in the
right subcutaneous pocket and anastomosed to the subclavian artery
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CPD

A novel counterpulsation device was developed by SCR Inc. (Louisville,
KY) in partnership with researchers at the University of Louisville [10]. This
device is currently undergoing pre-clinical trials[4]. It consists of a 30-ml
chamber, driveline, and outflow graft. The 30-ml chamber has a blood side and
air side that is separated by a membrane. The 30-ml chamber sits in the
pacemaker pocket of the right chest (figure 1). The driveline exits near the
bottom right side of the thoracic cavity. The outflow graft made of ePTFE was
designed to connect the 30-ml chamber to the right subclavian artery [3, 30]. The
device is pneumatically driven. Air is pumped in between the outer hard shell and
the inner membrane causing CPD ejection. This air is evacuated from the CPD
chamber during CPD filling. In contrast to IABP, the CPD fills during ventricular
systole and empties blood during diastole.

Figure 1. CPD sits in a HF patient’s right side underneath the Pectoralis
muscle via an infraclavicular incision. CPD is surgically anastomosed to
the right subclavian artery. The pump fills during systole and empties
during diastole through a valveless ePTFE cannula [2].
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Giridharan, et al. demonstrated equivalent or better hemodynamic benefits
with the CPD compared to 40-ml IABP in a computer simulation model of the
human circulatory system (Figure 2) [3]. Bartoli, et al. demonstrated a reduction
in LV oxygen consumption with the CPD compared to 40-ml IABP in a bovine
model (Figure 3). In addition to better hemodynamic benefits, the CPD
implantation is less invasive as it can be implanted in the right pacemaker pocket
without the need to access the thoracic cavity of the patient. Importantly, it has
the potential for chronic and ambulatory therapy as the device can be driven by a
portable pneumatic driver weighing ~5 lbs. A significant distinction between an
IABP and the CPD is that the IABP displaces blood in the native aorta while the
CPD moves blood in and out of the subclavian artery. This enables the ejection
and filling phases of the CPD to be longer than the balloon inflation and deflation
phases of the IABP. Faster balloon deflation is required in IABP to prevent
obstruction of the aorta during ventricular systole. This rapid deflation leads to
reverse coronary flow which diminishes myocardial perfusion augmentation and
hemodynamic benefits provided by the IABP.
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Figure 2. Giridharan, et al. demonstrated equivalent or better hemodynamic benefits with
the 30-ml CPD compared to 40-ml IABP. These pressure volume loops compare baseline
heart failure (solid) to the 30-ml CPD with early filling late ejection (dashed) and late filling
early ejection (dotted), and 40-ml IABP operating with early filling early ejection (dash-dot).
These data indicate lower mean ejection LV Pressure (LVP) and external work (LVEW) with
early filling late ejection algorithm compared with early filling early ejection and late filling
early ejection algorithms [3].
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Figure 3. Mean ± standard error for hemodynamic parameters during baseline,
counterpulsation device (CPD) support and intra-aortic balloon pump (IABP) support in a
bovine animal study during pharmacologically induced hypertension, hypotension, and
heart failure. LVEW, left ventricular external work; CAFd/LVEW, diastolic coronary artery
flow normalized to left ventricular external work; LVO2 Consumption, left ventricular
oxygen consumption during 1:1 support (IABP or CPD) normalized to baseline for that
physiological condition [1].
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CPD Anastomosis

CPD was originally developed to be anastomosed to a subclavian artery
that has a minimum diameter of 8 mm. CPD implantation is contraindicated for
patients with subclavian artery diameters of less than 8 mm as it cannot fully fill
and eject, leading to blood stasis and device thrombosis. The subclavian artery
size limits the number of patients that could benefit from CPD therapy [24, 25].
Therefore, as an alternative to the subclavian artery graft site, an aortic cannula
was developed to expand the patient population to individuals with a small
subclavian artery. Demonstrating the feasibility of the aortic anastomosis is one of
the main objectives of this thesis (see CHAPTER 3).

ECG Acquisition

ECG signal is required to time CPD filling and ejection. Epicardial ECG
leads increase the complexity of surgical implant and the risks of infection and/or
micro-shocks. In order to remove these unwanted risks, an alternative approach
is required to acquire ECG data while retaining signal fidelity. If the measured
ECG signal is not adequate or if the CPD is not synchronized with the native
heart, the CPD may increase ventricular workload and diminish myocardial
perfusion. Therefore, it is important to find a long-term, reliable solution to
accurately trigger the CPD.
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Besides the use of epicardial leads, other forms of ECG monitoring have
been considered for CPD [31]. For short-term devices such as IABP, surface
electrodes (3- to 12-lead configuration) are often used, but these leads may be a
significant clinical challenge due to motion artifacts and frequent need to replace
surface electrodes, especially in ambulatory patients [32]. Alternatively, leads
can be placed intravenously into the coronary sinus, which requires fluoroscopy
and introduces additional risks to the patient (dislodgment, fracture, thrombosis,
and infection) [15, 33, 34]. To overcome the limitations of current approaches, an
alternative subcutaneous lead system was developed.

Subcutaneous ECG Lead Development

Subcutaneous ECG leads were developed to provide high-quality signal,
and remove some of the negative effects of more invasive monitoring systems
[35-37]. Subcutaneous refers to the area of lead implantation right beneath the
skin. When joined with devices that reside in the pacemaker pocket of the right
chest, subcutaneous lead placement over the right chest as shown in Figure 4
provides adequate spacing to detect the ECG [30].
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Figure 4. Subcutaneous lead placement in bovine (left) and their analogous
placement in humans (right) [4].

SCR, Inc. completed the engineering development for integrated
subcutaneous ECG leads, which consisted of two generations of development as
shown in Figures 5-6. Fabrication was completed by OSCOR (Palm Harbor, FL).
The current subcutaneous ECG lead configuration consists of four individual
leads integrated into a single, electrically isolated cable. Each lead has a
transducer on its distal end (ECG sensing) and a single connector on the
proximal end that is attached to a signal conditioning and processing module that
generates an ECG waveform used to trigger and control the CPD. Each lead
uses a tine for fixation and a 1-cm exposed, non-insulated section for sensing
cardiac electric potential. Each of the four sensors is on a 25cm length lead to
provide maximum flexibility and separation distance of up to 50cm between a
pair of sensors. A separation of 15 cm enables detection of a voltage differential
(ECG) between paired sensors. The second group of four sensors provides a
back-up ECG signal in the unexpected event of lead migration or fracture in two
of the four leads of the first. Each group of four sensing leads are packaged into
11

a single silicone coated cable and integrated into a four-pin LEMO male
connector (PEI-Genesis), which is mated to a female receptor for ECG signal
conditioning and processing. The LEMO connectors have a threaded enclosure
as well as an extended end to provide strain-relief [32, 38].

Figure 5. Photograph of first generation subcutaneous ECG leads
fabricated by OSCOR and successfully tested in bovine model. The early
lead design did not include tunneling needle and fixation tine, but
demonstrated feasibility.

Figure 6. Photo of current ECG lead configuration complete with LEMO
connector and strain relief (left) as well as tunneling needle (green arrow)
and tine fixation (yellow arrow, upper right), and lead specifications (lower
right).
12

Warren, et al. tested the performance of the previous generation
subcutaneous lead system (6 bi-polar leads) in in-vivo animal experiments and
found the subcutaneous leads to provide accurate and reliable R-wave detection
as well as minimal lead migration, damage, and infection [4]. The lead has been
redesigned to be unipolar and the lead configuration has been simplified to 4
leads. The primary objective of this thesis was to test the new lead design and
configuration in acute bovine and chronic IHF bovine models. A secondary
objective of the thesis was to demonstrate the hemodynamic feasibility of aortic
cannulation of the CPD. The experimental design is shown in Figure 7.

Figure 7. Experimental outline of the acute and chronic animal studies.

13

CHAPTER 2 – CHRONIC in-vivo ANIMAL STUDY

INTRODUCTION

The objectives of this study were to 1) demonstrate chronic subcutaneous
lead efficacy in providing reliable cardiac signaling for proper device triggering and
2) quantify the amount of lead migration or other adverse events in long-term
implantable subcutaneous ECG leads in a chronic ischemic heart failure (IHF)
model. The study outline is shown in Table 1. Calves first underwent ischemic
heart failure (IHF) induction procedures (n=6). IHF calves and control (non-IHF
animal, n=1) were allowed to rest for 45 to 90 days in order to mature into a state
of advanced heart failure. Next, CPD and ECG lead implantation was performed.
ECG waveforms were collected using both epicardial and subcutaneous leads. At
the end of each experiment, calves were euthanized. If a calf died before data
could be acquired, then that calf was not averaged into the results.

A bovine model was selected because the anatomy of the heart and
vasculature is similar to that of humans and bovine are more docile compared to
porcine or ovine models when using devices with many externalized components.
All animals used were cared for in accordance with the University of Louisville
(UofL) Animal Care Committee and National Institutes of Health (NIH) guidelines.
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Experimental procedures were approved by the UofL Institutional Animal Care and
Usage Committee (IACUC).
Animal
ID
1
2
3
4

Length
of Study
1 day
10 days
30 days
30 days

Procedure
Date
1/30/14
5/12/14
9/30/14
9/10/14

Necropsy
Date
1/30/14
5/20/14
10/30/14
10/10/14

Termination Reason

died during surgery
died early from heart failure
full term
full term
euthanized early for pain
5
10 days
11/20/14
11/30/14
management reasons
6
31 days
1/8/15
2/9/15
full term
Table 1. Summary of electrocardiogram (ECG) lead efficacy and lead
migration testing in a bovine model of ischemic heart failure
implanted with a CPD anastomosed to the aorta.

MATERIALS AND METHODS

IHF Induction Procedure

In a bovine model, IHF was induced (n=5) along with a control (non-IHF,
n=1) for preparation of CPD implantation. Male Jersey calves (Oak Hill Genetics,
Ewing, IL) weighing 60 kg on arrival from vendor were first quarantined for 14 days
and treated with preventative medicine: Panacur (10mg/kg S.Q.), Marquis Paste
(20mg/kg, P.O.), Iron Dextran (2.0ml I.M.), Ivomec (1ml/50ky S.Q.), and Excenel
(2.2mg/kg

S.Q.).

After

passing

quarantine,

calves

underwent

cardiac

catheterization and IHF induction procedures using a target dose of polystyrene
embolization solution (1.3% 90μm microsphere solution). This solution was mixed
with equal amounts of saline and administered at a dose of 0.17 ml per kilogram of
body weight.
15

For IHF induction procedures, food and water was withheld for 20 hours
before surgery and the calves were given a Fentanyl transdermal patch for
analgesia. At the time of surgery, general anesthesia was administered with
Ketamine 4mg/kg and Valium 0.4mg/kg intravenously (IV) and later with
Isoflurane. External ECG leads were sutured to the calves for ECG monitoring
and pulse oximeters were used for intra-operative diagnostics. The following
drugs and fluids were used as necessary under the control of an anesthesiologist
to provide intraoperative support to the animal: Amiodarone, Lidocaine,
Dobutamine, Phenylepinephrine, Lactated Ringers Solution, Vitamin B Complex
Solution, Magnesium Sulfate, and Potassium Chloride. Every stage of the
procedure was carried out aseptically. A 3-4cm incision was made in the jugular
furrow. An AccessTM Vascular Access Port (VAP) was inserted into the jugular
vein. The VAP was tested for patency, flushed with 10ml saline, and locked with
taurolidine-citrate catheter solution. The VAP port was placed into the pocket and
secured to the muscle with 2-0 Vicryl sutures. An arteriotomy was performed
and a catheter was placed in the carotid artery and secured. Patency was
achieved and the catheter was connected to a pressure transducer line for intraoperative monitoring. A cordis sheath was placed into the carotid artery using
the modified Seldinger’s technique. Upon cardiac catheterization, spheres 90
microns in diameter were injected down the left anterior descending and
circumflex coronary arteries of the calf to induce heart failure. Upon completion of
the embolization procedure, the cordis sheath was removed and the arteriotomy
was closed. The calves were then transferred to post-operative care for a period
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of 45 to 90 days in order to mature into a state of advanced heart failure. Once
heart failure was diagnosed by an ejection fraction of less than 35% the calves
underwent a CPD implant procedure.

CPD, Subcutaneous, and Epicardial Lead Implant Procedure

The CPD implant procedure was similar to the embolization procedure in
terms of pharmaceutical use, vascular access, and the steps taken for intraoperative monitoring. However, Succinylcholine (30mg) was given before the
implant and a 25 cm incision was made over the 5th rib. The 5th rib was then
removed and two rib retractors were used for exposure. Blunt dissection and
electrical cautery were used to expose the aorta. Two groups of eight
subcutaneous ECG electrodes were tunneled in four quadrants surrounding the
chest incision and connected to the device externally. To track lead migration, the
leads were secured beneath the cutaneous layer using surgical staples which
were used as a placement reference (Figure 8). Three standard epicardial leads
(Medtronic, 5071 Screw-In Leads 53 cm long) were also implanted into the
epicardium for future waveform comparison [15]. Heparin was given to maintain
an ACT above 250 seconds. The outflow/inflow graft was cut to ideal anatomic
length. The aorta was partially clamped, an aortotomy was made, and the CPD
graft was anastomosed using 3-0 Prolene suture. Hemostasis was checked and
the graft was de-aired and connected to the CPD device. A 24mm flow probe was
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placed on the outflow graft and tunneled out next to the driveline for post-operative
monitoring. A chest tube was inserted and secured for drainage.

Figure 8. Tunneling of the subcutaneous ECG lead (red arrow, upper left).
Surgical staples (purple arrow) being placed for subcutaneous ECG lead
fixation and to serve as a landmark for evaluating lead migration at
necropsy (upper right). Aortic anastomosis (lower left) and location of ECG
leads (white arrows, lower right).

Post-Operative Procedure

After CPD implant procedure, the calves were transferred to the postoperative care area and monitored continuously for 30 days or until the study
was terminated under order of the attending veterinarian for pain management
reasons. Following admission to post-operative recovery, subcutaneous and
epicardial waveforms were recorded for 30 seconds at hourly intervals. Both
18

signals were conditioned using the CPD driver (iPulse, Abiomed, Danvers, MA).
The waveforms were collected at 400 Hz (National Instruments, AT-MIO-16E-10,
Austin, TX), and were filtered using a clinical standard 60 Hz notch filter
(Frequency Devices, Ottawa IL). All waveforms were visualized and recorded
using a custom, good laboratory practice (GLP) approved data acquisition system
(DAQ).

Euthanasia Procedures

After 30 days of device usage and data acquisition, calves were examined
under fluoroscopy, heparinized, and subsequently euthanized with a bolus of
Beuthanasia solution (30ml I.V.) followed by two boluses of KCl (30mEq). This
procedure is in accordance with the recommended practices of the 2007 American
Veterinary Medical Association Guidelines on Euthanasia. The calves were
immediately exsanguinated and a full necropsy was performed for each calf to
detect the occurrence of internal adverse events or infection. To quantify lead
migration and lead damage, the lead sensing ends were visually compared to
their placement staples using a metric ruler and the difference was recorded.
Photographic documentation of lead migration was captured (Figure 9). The
veterinarian completed a gross examination to detect external adverse events.
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Figure 9. Photograph of subcutaneous lead migration (red arrow) in calves
at the termination of the study. Staples were placed on the skin upon lead
implantation to be used as a reference for original lead placement. Only
one lead was found to migrate more than 0.5cm as shown above.

Post-Processing

Post-euthanasia, subcutaneous and epicardial ECG waveforms from the
collected data epochs were analyzed to compare detection rates using computer
software (MATLAB, The Mathworks, Natick, MA). For R-wave comparison,
waveforms were analyzed on a beat-to-beat basis using custom m-files written in
MATLAB (Mathworks, Natick MA). The original scripts published by Warren, et al.
required input of the epicardial ECG waveform along with three separate bi-polar
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subcutaneous ECG waveforms [4]. During this study, a total of two ECG
waveforms were saved (1 epicardial, 1 subcutaneous). Therefore, the scripts were
modified to allow for the difference in signal format. Once both ECG waveforms
were loaded into MATLAB, every subcutaneous (test) R-wave or lack thereof was
compared to the epicardial (control) R-wave in each data epoch and classified as a
true positive, false positive, or false negative R-wave. The same R-wave detection
mechanism used in the CPD driver was used when detecting and comparing Rwaves for both signals. The first function of this program aligns the first R-waves
of the subcutaneous and epicardial waveforms to account for the difference in
lead lengths. Although the time difference between peaks in each waveform is
small, any misalignment could potentially lead to a hindrance in R-wave
detection. To do this, the program searches each waveform for the first local
maximum indicated by user input of a specific time window. Once the waveforms’
first QRS peaks are identified they are aligned by splicing data points from the
beginning of the subcutaneous waveform and truncating the end of the epicardial
waveform. Next, a 1-50 Hz (N=700) finite impulse response band-pass filter was
implemented for optimal detection and to eliminate baseline drift.

For R-wave comparison, the signals were derived to detect major
differences in slope before and after the R-wave. The program was given a
threshold for the first three R-waves and then a bootlegging mechanism
propagated the detection using a percentage of the average of the last three Rwave thresholds. If the QRS complex was detected in both waveforms, the signal
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was classified as true positive. A maximum time difference of 150 ms between
epicardial and subcutaneous ECG was used to calculate true positive in
accordance with ANSI/AAMI EC 57 standard. If the QRS was detected in the
epicardial waveform, but not in the subcutaneous waveform it was classified as a
false negative. If the QRS was detected in the subcutaneous waveform, but not in
the epicardial waveform it was classified as a false positive. These classifications
were used to calculate Positive Predictive Value (1) and Sensitivity (2). If a signal
was not collected or there was electrical noise during data capture, that data epoch
was not used in the average calculations.

Positive Predictive Value (PPV) =
Sensitivity =

𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒

𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒

(1)

(2)

PPV is a representation of type I error and sensitivity is a representation of
type II error. Of the two types of error, type I error is more detrimental for
counterpulsation therapy. If a false R-wave is falsely detected (type I error), it
would cause an unsynchronized filling and ejection which may increase LVEW and
diminish coronary perfusion and advance the state of heart failure. If an R-wave is
not detected (Type II error), the device would not fill or eject for that heart beat and
would not adversely affect the baseline hemodynamics. If R-waves are not
detected (Type II error) for a prolonged period, the CPD driver would switch to a

22

temporary ‘wash mode’, and slowly wash blood in and out of its 30 ml chamber to
protect the patient from thrombosis.

RESULTS

Out of the six calves that survived IHF induction, one died after CPD
implantation before any data could be acquired, and was therefore not included
in this summary. From the remaining five calves, 791 data epochs were
measured and recorded for chronic IHF calves (n=4) and control (n=1).
Subcutaneous leads provided 98.8% PPV and 98.8% sensitivity when compared
to epicardial leads (Table 2).

Length
Total
Data
Calf
of
Heart
PPV
Sensitivity
Epochs
Study
Beats
1
30-day
347
18975
0.994 ± 0.023 0.985 ± 0.047
2
10-day
71
4429
0.996 ± 0.014 0.988 ± 0.034
3
6-day
27
1371
0.978 ± 0.041 0.958 ± 0.074
4
30-day
289
15168
0.985 ± 0.030 0.995 ± 0.021
5
30-day
57
2829
0.967 ± 0.048 0.981 ± 0.046
Totals
Chronic
791
42772
0.988 ± 0.030 0.988 ± 0.040
Table 2. Positive predictive value (PPV) and sensitivity of R-wave detection
calculated from subcutaneous ECG recordings. Each data epoch consists
of 30 seconds of ECG signaling. Values are listed as mean ± standard error.

An example of acquired subcutaneous and epicardial waveforms are
shown in Figure 10. One chronic calf was euthanized ten days after CPD implant
at the discretion of the attending veterinarian for pain management and another
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died from heart failure symptoms six days after CPD implant. The accumulated
epochs offered a total of 416.5 minutes of recorded ECG waveforms.

Figure 10. Subcutaneous (dashed line) ECG demonstrated a 98.9% PPV and
98.9% sensitivity for counterpulsation timing compared to epicardial (solid
line) ECG leads.

Lead migration (n=1, >0.05 cm) and lead fracture (n=1) were only
observed in two out of 40 leads and did not adversely impact triggering efficacy.

DISCUSSION

Upon inspection of the recorded ECG signals, electrical noise was found.
However, if a QRS complex could be seen visually, then custom m-files were
used to compare R-wave detection rates. After excluding incomplete data epochs
(missing

epicardial

waveforms,

missing
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subcutaneous

waveforms,

or

indiscernible waveforms), subcutaneous ECG leads were found to have a 98.8%
PPV and 98.8% sensitivity. False positive and false negative beats were
calculated in comparison to the epicardial lead ECG signal and not the actual
myocardial contraction. Thus, even if the subcutaneous lead correctly picked up
the ECG signal but epicardial lead was erroneous and vice versa, it still
registered as a false positive and false negative, reducing PPV and sensitivity
values for the subcutaneous leads. Despite these limitations, the performance of
the epicardial ECG leads exceeded the design specifications of 95% PPV and
95% sensitivity. These results demonstrate that the subcutaneous leads are
equivalent to epicardial leads for counterpulsation device triggering and R-wave
detection. Noise and motion artifacts don’t significantly alter the detection rate.

Two of 40 subcutaneous leads had a migration or fracture. However, in
the case of a loss in signal or reduced signal strength, the controller
automatically switches to another lead pair for ECG signaling. This provides
redundancy and the detection algorithm embedded in the CPD driver
automatically picks the best ECG signal available for device timing [39].
Therefore, lead migration and fracture did not diminish the efficacy of the CPD
due to the redundant design.

Adverse events were reported by the veterinarian throughout the duration
of the study and upon termination of the study (necropsy). There were no
hemolysis, thrombus formation in device, graft or end organs, or vascular injury

25

events associated with the CPD. The aortic cannulation was patent throughout
the duration of the study. A limitation of the study was that the subcutaneous and
epicardial signals were first input into the CPD driver for processing, filtering, and
amplification before being output into the GLP compliant DAQ which removes the
ability to analyze raw signals, and increases the opportunity for noise to distort
the saved signals.
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CHAPTER 3 – ACUTE in-vivo ANIMAL STUDY

INTRODUCTION

The two objectives of this study were to 1) demonstrate acute
subcutaneous lead efficacy in providing reliable cardiac signaling for proper device
triggering and 2) demonstrate feasibility of aortic CPD cannulation under
pharmacologically induced conditions. The outline of the study is shown in Table 3.

Animal Procedure Necropsy
Reason for Termination
ID
Date
Date
1
12/6/13
12/6/13
full term
2
12/9/13
12/9/13
full term
3
3/18/14
3/18/14
full term
4
5/6/14
5/6/14
died during surgery
5
3/14/14
3/14/14
full term
Table 3. Summary of acute calves used for ECG lead testing and
hemodynamic testing.

For this study, an acute, non-HF model was used (n=5). CPD,
subcutaneous leads, and epicardial leads were implanted along with pressure and
flow sensors for hemodynamic waveform acquisition. ECG and hemodynamic
waveforms were simultaneously collected during normal and pharmacologically
induced hypertension, hypotension, and heart failure test conditions. At the end of
each experiment, the animals were euthanized.
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MATERIALS AND METHODS

Following the CPD implantation procedures outlined previously (Chapter 3),
14 lines of instrumentation were implanted before the CPD was implanted in
preparation for hemodynamic testing. Specifically, fluid-filled catheters were
inserted into the left carotid artery and left jugular vein to acquire arterial pressure
(ArtP) and central venous pressure (CVP), respectively. High fidelity pressure
catheters (Millar Instruments, Houston, TX) were used to measure left atrial
pressure (LAP) and aortic pressure (AoP). Left ventricular pressure (LVP) and left
ventricular volumes (LVVol) were collected using a volume conductance catheter
(Transonic Systems Inc., Ithaca, NY). Transit time flow probes (Transonic Systems
Inc., Ithaca NY) of varying sizes were used to obtain flow waveforms. Flow probes
were covered with transonic signal enhancement liquid and then wrapped around
the left carotid artery (CdAF), left main coronary artery (CAF), aorta proximally to
the heart (AOFp), aorta distally from the heart (AOFd), and pulmonary artery
(PAF). The electrical cardiac signals (subcutaneous, epicardial, and surface) were
also routed to the DAQ to be acquired for future use. External ECG leads were
used only for intra-operative monitoring. All lines of instrumentation except surface
ECG electrodes were tunneled out of the lower thoracic cavity of each bovine and
connected to the custom GLP DAQ. Both of the implanted ECG lead systems were
routed directly into the CPD driver to be used for synchronized device triggering.
From there, the filtered, amplified ECG waveforms were sent to the DAQ to be
collected.
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Hemodynamic waveforms were captured and recorded during: (1) normal
(mean arterial pressure between 65 - 120 mmHg); (2) hypotension (mean arterial
pressure < 65 mmHg induced by Nitroprusside); (3) hypertension (mean arterial
pressure > 120 mmHg induced by Phenylephrine); and (4) heart failure (a 50%
decrease in PAF induced by Esmolol). All conditions were allowed to normalize for
15 minutes before data was acquired. In each condition, 30 second data sets were
taken of no pump support, 1:2 support, and 1:1 support. Experiments ended with
euthanasia and a full necropsy to detect adverse events totaling experiment time
from 6 to 8 hours. Complete photographic documentation of adverse events was
recorded.

After the calf was euthanized, the Millar catheters and the Transonic
Systems Inc. pressure-volume catheters were calibrated using a sealed pressure
chamber at -5mmHg, 50mmHg, 100mmHg, and 150mmHg. The Transonic flow
probes were calibrated electronically in a stagnant bowl of saline at 0 and 1
Volts.

All waveforms were saved using the GLP compliant DAQ system. For
ECG waveforms, post-processing was performed as described in chronic
experiments (Chapter 3). For hemodynamic waveforms, post-processing was
performed using computer software (MATLAB, The Mathworks, Natick, MA).
Specifically, Hemodynamic Evaluation and Assessment Tool (HEART) was used
to determine hemodynamic efficacy [40]. Blood pressure and flow waveforms
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were input into the program to calculate heart rate (HR), stroke volume (SV),
cardiac output (CO), mean coronary artery flow (CAFm), left ventricular peak
systolic pressure (LVPSP), left ventricular end diastolic pressure (LVEDP), left
atrial pressure (LAP), left ventricular end systolic volume (LVVes), left ventricular
end diastolic volume (LVVed), LVEW, mean aortic pressure (AoPm), and aortic
pulse pressure (AoP pulse). All parameters were averaged to establish one
mean value and were subsequently analyzed in Minitab (Minitab Inc., State
College, PA). Two-tailed paired t-tests were used to compare no support to 1:1
support at each induced pharmacologic condition. A P-value of 0.05 or a
confidence interval of 95% was considered statistically significance.

RESULTS

Out of the four calves that survived cardiac surgery, only two had
epicardial and subcutaneous waveforms with distinguishable QRS complexes. 42
data epochs were measured and recorded in these two calves. The
subcutaneous leads had a 99.7% PPV and 100% sensitivity compared to
epicardial leads (Table 4).

The CPD cannulated to the aorta diminished left ventricular (LV) external
work (up to 31%), LV end diastolic volume by 31ml (247ml vs 278.2ml at
baseline) and end systolic volumes by 42ml (139.2ml vs 181.2ml at baseline)
during pharmacologically induced heart failure (HF). Cardiac output, aortic mean,
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pulse pressures, and mean coronary artery flow were augmented by up to
17.9%, 13.0%, 62.3%, and 52.4%, respectively (Table 5). The hemodynamic
benefits of the CPD were not as profound for normal, hypotension and
hypertension test conditions compared to HF test condition.

Calf
1
2
Totals

Length
of
Study
1-day
1-day
Acute

Data
Epochs
16
23
39

Total
Heart
Beats
697
1145
1842

PPV

Sensitivity

0.993 ± 0.018
1.000 ± 0.000
0.997 ± 0.099

1.000 ± 0.000
1.000 ± 0.000
1.000 ± 0.000

Table 4: Positive predictive value (PPV) and sensitivity of R-wave detection
calculated from intra-operative subcutaneous ECG recordings. Each data
epoch consists of 30 seconds of ECG signaling. Values are listed as mean
± standard error.

31

32

88±9
87±5

1:2

1:1

CO

101±7

87±5
98±9

1:2

1:1

93±5
92±5

1:2

1:1

11.6±0.4

11.6±0.4

11.7±0.0

12.5±1.0

12.1±1.4

CAFm

122±18

130±20

131±17

234±20

199±30

222±33

102±8

102±10

118±12

73±12

53±9

48±27

(mL/min)

102.1±10.7

107.9±11.9

106.7±10.8

188.4±25.0

169.2±16.8

178.8±30.9

67.7±2.1

85.1±13.8

81.1±10.3

47.4±3.6

52.2±4.5

48.1±4.9

12.8±1.8

12.2±0.9

13.0±1.0

15.9±1.4

15.3±1.6

16.0±0.6

12.5±0.9

13.6±1.7

10.3±2.1

16.6±1.7

18.6±1.0

15.9±3.5

LVEDP
(mm Hg)

LVPSP
(mm Hg)

LAP

8.8±0.7

8.4±0.9

8.6±1.6

10.0±0.4

9.6±0.5

9.8±0.7

8.3±1.0

8.6±0.9

8.7±1.1

13.5±0.6

14.1±1.4

14.0±1.2

(mm Hg)

49.3±55.3

64.2±44.4

81.3±20.4

115.6±56.5

91.8±56.5

94.6±52.3

123.9±19.2

125.5±19.4

128.4±24.2

139.2±54.4

159.1±24.2

181.2±29.1

(ml)

LVVes

217.0±0.3

224.7±2.1

243.1±19.1

293.0±83.2

207.9±73.2

297.5±85.5

260.4±50.9

262.1±51.1

228.6±23.3

247.2±2.4

274.3±25.2

278.0±21.0

(ml)

LVVed

LV EW

9859±630

10606±946

10810±1093

18191±1287

18172±145

18147±1413

3394±1247

4842±467

4640±592

987±440

1978±341

1434±654

(mmHg-ml)

78.1±3.5

82.3±5.9

79.1±6.2

140.4±18.9

124.4±8.1

129.3±6.4

43.7±1.5

45.0±1.6

44.6±1.6

34.9±3.8

35.4±5.7

30.9±2.9

(mm Hg)

AoP mean

41.9±5.2

39.0±4.7

33.1±3.5

50.4±4.6

42.3±8.6

37.7±5.7

42.3±5.7

44.1±8.1

33.8±2.7

38.0±7.2

31.8±10.4

23.4±5.6

(mm Hg)

AoP pulse

Table 5. Hemodynamic parameters during acute counterpulsation therapy with the CPD device cannulated to the aorta
in calves with pharmacologically induced hypertension, hypotension, and heart failure. HR, heart rate; SV, stroke
volume; CO, cardiac output; CAFm, mean coronary artery flow; LVPSP, left ventricular peak systolic pressure; LVEDP,
left ventricular end diastolic pressure; LAP, left atrial pressure; LVVes, left ventricular end systolic volume; LVVed, left
ventricular end diastolic volume; LVEW, left ventricular external work; AoP mean, mean aortic pressure; AoP pulse,
aortic pulse pressure

91±3

Baseline

Normal

96±5

Baseline

Hypertension
13.2±1.3

8.5±0.9

108±13

1:1

8.6±1.0

109±15

1:2

8.5±0.9

5.3±0.3

5.7±0.4

4.5±0.2

(L/min)

Baseline

Hypotension

84±6

Baseline

Heart Failure

HR
(bpm)

Condition

and Support

Pressure-volume loop figures represent the LVEW and ventricular
hemodynamic conditions during heart failure, hypertension, hypotension, and
normal test conditions (Figures 11, 13, 15, 17). LVP, AoP, and CAF waveforms
demonstrate changes in perfusion and pulsatility between each test condition
(Figures 12, 14, 16, 18). The hemodynamic benefits from heart failure show the
most significant improvement with CPD support (Figures 11-12). CPD support
diminished LVEW, left ventricular end systolic and end diastolic volumes, and
augmented coronary perfusion, aortic pressures and aortic pulsatility during heart
failure (Figures 11-12). The hemodynamic benefits of CPD support were not
statistically discernable from baseline values.

Figure 11. Pressure-volume loops obtained from an acute animal study at
baseline (solid, no CPD support), and 1:1 CPD support (dashed) during a
pharmacologically induced heart failure test condition. These PV loops
demonstrate the reduction in LVEW, end systolic volume, and end diastolic
volume with CPD support.
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Figure 12. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and
coronary artery flow waveforms obtained during a pharmacologically
induced heart failure test condition at baseline (no CPD support), 1:2
support, and 1:1 support. These waveforms indicate a lower ventricular
ejection pressure and higher aortic diastolic pressures (arrows, top) and
coronary artery flow (arrows, bottom) during counterpulsation support.
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Figure 13. Pressure-volume loops obtained at baseline (solid, no CPD
support) and 1:1 CPD support (dashed) during a pharmacologically
induced hypertension test condition. The hemodynamic benefits such as
reductions in LVEW, end systolic volume, and end diastolic volume are not
evident compared to the heart failure test condition as the stroke volume of
the native heart (135 ml) was much greater than the counterpulsation
device volume (30 ml).

35

Figure 14. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and
coronary artery flow waveforms obtained during a pharmacologically
induced hypertension test condition at baseline (no CPD support), 1:2
support, and 1:1 support. The hemodynamic benefits such as lower
ventricular ejection pressure and higher aortic diastolic pressures (arrows,
top) and coronary artery flow (arrows, bottom) are not evident compared to
the heart failure test condition as the stroke volume of the native heart (135
ml) was much greater than the counterpulsation device volume (30 ml).
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Figure 15. Pressure-volume loops obtained at baseline (solid, no CPD
support), and 1:1 CPD support (dashed) during a pharmacologically
induced hypotension test condition. The hemodynamic benefits such as
reductions in LVEW, end systolic volume, and end diastolic volume are not
evident compared to the heart failure test condition as the stroke volume of
the native heart (82 ml) was much greater than the counterpulsation device
volume (30 ml).
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Figure 16. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and
coronary artery flow waveforms obtained during a pharmacologically
induced hypotension test condition at baseline (no CPD support), 1:2
support, and 1:1 support. These waveforms indicate a lower ventricular
ejection pressure and higher aortic diastolic pressures (arrows, top) and
coronary artery flow (arrows, bottom) during counterpulsation support.

38

Figure 17. Pressure-volume loops at baseline (solid, no CPD support), and
1:1 CPD support (dashed) during a normal test condition. The
hemodynamic benefits such as reductions in LVEW, end systolic volume,
and end diastolic volume are not evident compared to the heart failure test
condition as the stroke volume of the native heart (128 ml) was much
greater than the counterpulsation device volume (30 ml).
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Figure 18. Aortic pressure (AoP, dotted), LV pressure (LVP, solid), and
coronary artery flow waveforms obtained during a normal test condition at
baseline (no CPD support), 1:2 support, and 1:1 support. Lower ventricular
ejection pressure and higher aortic diastolic pressures (arrows, top) and
coronary artery flow (arrows, bottom) during counterpulsation support are
not as evident compared to the heart failure test condition as the stroke
volume of the native heart (128 ml) was much greater than the
counterpulsation device volume (30 ml).
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DISCUSSION

The >99% PPV and sensitivity values demonstrated that the epicardial
leads can adequately trigger the CPD during a wide range of physiologic
conditions.

Hemodynamically,

cardiac output,

coronary

perfusion,

aortic

pressure, and aortic pulsatility showed an increasing trend and decreases were
observed in end-systolic and end-diastolic left ventricular volumes and LVEW.
The benefits of counterpulsation are most pronounced when counterpulsation
device volume is similar to the stroke volume of the native heart and at low aortic
compliances [41]. The hemodynamic waveforms from the animal study closely
resembles couterpulsation waveform morphology observed clinically and in an
earlier computer simulation study [42]. However, the hemodynamic benefits of
CPD support was not evident at normal, hypertensive, and hypotensive
conditions in the acute animal study as the stroke volume of the native heart
(128, 135, and 82 ml respectively) was much greater than the counterpulsation
device volume (30 ml). Further, the aortic compliance of a calf is significantly
greater than that of a human with HF [41]. Due to these factors and low sample
size (n=3), statistical significance could not be ascertained between baseline and
1:1 CPD support, but improving hemodynamic trends with CPD support
demonstrate the feasibility of aortic cannulation. While aortic anastomosis would
increase the invasiveness of device implantation in patients with small subclavian
arteries, chronic counterpulsation may enable earlier intervention (Class III) and
arrest the progression of HF.
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The hemodynamic benefits provided by the CPD anastomosed to the
aorta would be slightly higher than the benefits provided by the CPD
anastomosed to the subclavian artery due to energy losses associated with the
CPD being farther away from the aorta [21]. The hemodynamic parameters of the
CPD anastomosed to the carotid artery in an acute bovine model (n=12) from an
earlier study is presented in Table 6 [1].

Physiological
Condition
Normal
Hypertension

Hypotension

Heart
Failure

Support
Baseline
Baseline
CPD
Baseline
CPD
Baseline
CPD

1:2
1:1
1:2
1:1
1:2
1:1

HR
(bpm)
78 ± 4
73 ± 4
77 ± 5
76 ± 4

CO
(L/min)
8.0 ± 0.0
8.1 ± 0.5
8.2 ± 0.6
8.2 ± 0.6

CAFdia
(mL/min)
207 ± 46
285 ± 43
305 ± 49
314 ± 49

LVPSP
(mm Hg)
103 ± 3
138 ± 3
138 ± 3
137 ± 3

LVPEDP
(mm Hg)
16 ± 2
19 ± 2
19 ± 3
19 ± 2

LAP
(mm Hg)
14 ± 2
14 ± 2
15 ± 2
14 ± 2

70 ± 3
72 ± 3
71 ± 3
66 ± 3
67 ± 3
67 ± 3

6.8 ± 0.5
6.8 ± 0.7
6.8 ± 0.6
6.0 ± 0.3
6.2 ± 0.3
6.1 ± .03

141 ± 33
155 ± 33
173 ± 43
139 ± 35
153 ± 36
159 ± 37

77 ± 2
76 ± 2
74 ± 2
89 ± 5
88 ± 5
84 ± 4

11 ± 1
10 ± 1
10 ± 1
22 ± 1
22 ± 1
21 ± 1

9±1
9±1
8±1
15 ± 1
16 ± 1
15 ± 1

TABLE 6. Hemodynamic parameters during acute counterpulsation
therapy with the CPD cannulated to carotid artery in calves with
pharmacologically induced hypertension, hypotension, and heart
failure [1].

A limitation of the study is that the hemodynamic effects were observed
under pharmacologically induced, acute conditions. Thus, the state of the animal
was never completely stable due to the half-life of drugs. Chronic pathologies or
a significantly higher sample size (n=10-12) may be required for demonstrating
statistically significant hemodynamic benefit.
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CHAPTER 4 - CONCLUSION

This study demonstrates the long-term efficacy of using subcutaneous
leads to provide an accurate, reliable ECG waveform for R-wave detection to
trigger counterpulsation devices shown by 98.9% PPV and 98.9% sensitivity for
all test conditions. Since the adverse events associated with lead migration and
lead fracture didn’t impact device triggering, use of subcutaneous leads in future
clinical therapies is promising. Additionally, this study demonstrates the feasibility
of aortic cannulation for patients with small subclavian arteries.

43

CHAPTER 5 – LIST OF REFERENCES

1.

Bartoli, C.R., et al., A novel subcutaneous counterpulsation device: acute
hemodynamic efficacy during pharmacologically induced hypertension,
hypotension, and heart failure. Artif Organs, 2010. 34(7): p. 537-45.

2.

Company, B.W.A.B.H., Abiomed Announces Symphony, an Implantable
Synchronized Heart Pump. 2011, AHA Scientific Sessions.

3.

Giridharan, G.A., et al., Predicted hemodynamic benefits of
counterpulsation therapy using a superficial surgical approach. Asaio j,
2006. 52(1): p. 39-46.

4.

Warren, S., et al., Feasibility of Subcutaneous ECG Leads for
Synchronized Timing of a Counterpulsation Device. Cardiovascular
Engineering and Technology, 2011. 3(1): p. 17-25.

5.

Mozaffarian, D., et al., Heart disease and stroke statistics--2015 update: a
report from the American Heart Association. Circulation, 2015. 131(4): p.
e29-322.

6.

Wilson, K.B., Helath Care Costs 101. California Healthcare Foundation,
2012.

7.

Muntwyler, J., et al., One-year mortality among unselected outpatients
with heart failure. Eur Heart J, 2002. 23(23): p. 1861-6.

8.

Pitt, B., et al., The effect of spironolactone on morbidity and mortality in
patients with severe heart failure. Randomized Aldactone Evaluation
Study Investigators. N Engl J Med, 1999. 341(10): p. 709-17.

9.

e-Statistics Report on Transplant, Waiting List and Donor Statistics, in
2012 Summary Statistics, January 1 to December 31st, 2012. . Canadian
Institute for Health Information., 2008.

10.

Koenig, S.C., et al., Acute hemodynamic efficacy of a 32-ml subcutaneous
counterpulsation device in a calf model of diminished cardiac function.
Asaio j, 2008. 54(6): p. 578-84.

11.

Moskowitz, A.J., E.A. Rose, and A.C. Gelijns, The cost of long-term LVAD
implantation. Ann Thorac Surg, 2001. 71(3 Suppl): p. S195-8; discussion
S203-4.

44

12.

Westaby, S. and P. Poole-Wilson, Mechanical circulatory support in the
UK. Bmj, 2007. 334(7586): p. 167-8.

13.

Costs Comparable Per Patient Between Impella and Intra-Aortic Balloon
Pump at 90 Days. Diagnostics and Interventional Cardiology.

14.

Mozaffarian, D., et al., Heart Disease and Stroke Statistics-2016 Update:
A Report From the American Heart Association. Circulation, 2016. 133(4):
p. e38-e360.

15.

Kautzner, J., et al., Technical aspects of implantation of LV lead for
cardiac resynchronization therapy in chronic heart failure. Pacing Clin
Electrophysiol, 2004. 27(6 Pt 1): p. 783-90.

16.

Nanas, J.N. and S.D. Moulopoulos, Counterpulsation: historical
background, technical improvements, hemodynamic and metabolic
effects. Cardiology, 1994. 84(3): p. 156-67.

17.

Papaioannou, T.G. and C. Stefanadis, Basic principles of the intraaortic
balloon pump and mechanisms affecting its performance. Asaio j, 2005.
51(3): p. 296-300.

18.

Bolooki, H., ed. , Clinical Application of the Intra-Aortic Balloon Pump
Futura: New York, 1998(3rd edition).

19.

Santa-Cruz, R.A., M.G. Cohen, and E.M. Ohman, Aortic counterpulsation:
a review of the hemodynamic effects and indications for use. Catheter
Cardiovasc Interv, 2006. 67(1): p. 68-77.

20.

Tsagalou, E.P., M.I. Anastasiou-Nana, and J.N. Nanas, Intra-aortic
balloon counterpulsation for the treatment of myocardial infarction
complicated by acute severe heart failure. Congest Heart Fail, 2009.
15(1): p. 35-40.

21.

Kolyva, C., et al., Discerning aortic waves during intra-aortic balloon
pumping and their relation to benefits of counterpulsation in humans. J
Appl Physiol (1985), 2009. 107(5): p. 1497-503.

22.

Scheidt, S., et al., Intra-aortic balloon counterpulsation in cardiogenic
shock. Report of a co-operative clinical trial. N Engl J Med, 1973. 288(19):
p. 979-84.

23.

Lefemine, A.A., et al., Assisted circulation. III. The effect of synchronized
arterial counterpulsation on myocardial oxygen consumption and coronary
flow. Am Heart J, 1962. 64: p. 789-95.

45

24.

Weiss, A.T., et al., Regional and global left ventricular function during
intra-aortic balloon counterpulsation in patients with acute myocardial
infarction shock. Am Heart J, 1984. 108(2): p. 249-54.

25.

Kern, M.J., et al., Enhanced coronary blood flow velocity during intraaortic
balloon counterpulsation in critically ill patients. J Am Coll Cardiol, 1993.
21(2): p. 359-68.

26.

Ishihara, M., et al., Effects of intraaortic balloon pumping on coronary
hemodynamics after coronary angioplasty in patients with acute
myocardial infarction. Am Heart J, 1992. 124(5): p. 1133-8.

27.

Sun, J.C., R.K. Ghanta, and M.J. Davidson, Highlights from the
Transcatheter Cardiovascular Therapeutics Conference 2010:
Washington, DC, September 21-25, 2010. J Thorac Cardiovasc Surg,
2011. 142(2): p. 468-71.

28.

Sun, B., Sunshine: Chronic Aortic Counterpulsation for Class III Heart
Failure. Transcatheter Cardiovascular Therapeutics, 2009.

29.

Jeevanandam, V., et al., Circulatory assistance with a permanent
implantable IABP: initial human experience. Circulation, 2002. 106(12
Suppl 1): p. I183-8.

30.

Fotuhi, P., et al., R-wave detection by subcutaneous ECG. Possible use
for analyzing R-R variability. Ann Noninvasive Electrocardiol, 2001. 6(1):
p. 18-23.

31.

Goldich, G., Getting in sync with intra-aortic balloon pump therapy.
Nursing, 2011. 41 Suppl: p. 10-3.

32.

Lobodzinski, S.S. and M.M. Laks, Comfortable textile-based
electrocardiogram systems for very long-term monitoring. Cardiol J, 2008.
15(5): p. 477-80.

33.

Schwartzman, D., et al., Postoperative lead-related complications in
patients with nonthoracotomy defibrillation lead systems. J Am Coll
Cardiol, 1995. 26(3): p. 776-86.

34.

Lawton, J.S., et al., Sensing lead-related complications in patients with
transvenous implantable cardioverter-defibrillators. Am J Cardiol, 1996.
78(6): p. 647-51.

35.

Bardy, G.H., et al., An entirely subcutaneous implantable cardioverterdefibrillator. N Engl J Med, 2010. 363(1): p. 36-44.

36.

Andrew Grace, M.H., Warren Smith, Andrey Ardashev, Riccardo Cappato,
Gust Bardy, Evaluation of four distinct subcutaneous implantable
46

defibrillator (S-ICD®) lead systems in humans. Heart Rhythm, 2006(3): p.
S128-S129.
37.

Juan F. Iglesias, D.G., Patrizio Pascale, Etienne Pruvot, The implantable
loop recorder: a critical review. THE NEW DEVICE, 2009. 12(3): p. 85-93.

38.

van Dam, P., et al., Improving sensing and detection performance in
subcutaneous monitors. J Electrocardiol, 2009. 42(6): p. 580-3.

39.

Hanlon-Pena, P.M. and S.J. Quaal, Intra-aortic balloon pump timing:
review of evidence supporting current practice. Am J Crit Care, 2011.
20(4): p. 323-33; quiz 334.

40.

Schroeder, M.J., et al., HEART: an automated beat-to-beat cardiovascular
analysis package using Matlab. Comput Biol Med, 2004. 34(5): p. 371-88.

41.

Koenig, S.C., et al., Human, bovine and porcine systematic vascular input
impedances are not equivalent: implications for device testing and
xenotransplantation in heart failure. J Heart Lung Transplant, 2008.
27(12): p. 1340-7.

42.

Moulopoulos, S.D., The limits of counterpulsation. Int J Artif Organs, 1993.
16(12): p. 803-5.

47

CHAPTER 6 – CURRICULUM VITAE

Stephen R. Carnahan
Graduate Student
Department of Bioengineering
University of Louisville
Louisville, Kentucky, USA
859-620-7296
srcarn02@icloud.com

Education
2016 University of Louisville

Master of Engineering in Bioengineering

GPA:----2015 University of Louisville

Bachelor

of

Science

in

Bioengineering

GPA: 3.76
2011 Walton Verona High School High

School

GPA: 3.99

Skills


SolidWorks



Microsoft Office



MATLAB



Anatomy and Physiology



Medical Devices



Statistics



Minitab

48

Diploma

Academic and Professional Experience
2013-2015

Three Academic Research Co-ops, Advanced Heart Failure

Research at the Cardiovascular Innovation Institute (total: 1 year)


Provided technical support for many grant and industry sponsored studies,
including hemolysis testing for mechanical circulatory support devices.



Assisted with instrumentation and data collection during open-heart surgery
on calves.



Observed VAD operations and collected myocardial samples for a tissue
repository.



Learned techniques related to instrument preparation & handling, inducing
anesthesia, cardiac defibrillation, tissue procurement, tissue transportation &
storage, administering regional blood flow microspheres, fluoroscopy exams,
skin electrocautery & suturing, electrocardiograms, and hemodynamic exams.

2014


Part-time University of Louisville Employment, Tutoring

Tasked with helping college students understand mathematical concepts and
techniques from basic Algebra to Calculus II
2012-2013



Part-time University of Louisville Employment, Test Grader

Tasked with grading Calculus tests and assessing depth of knowledge for
Calculus I, II, and III material
2010-2011



Part-time Kroger Employee, Courtesy Clerk

Tasked with pushing carts into the building and bagging customers’ groceries
49

Academic and Professional Honors and Awards
Trustees Academic Scholarship

Fall 2011 - Spring 2016

Dean’s List

Spring 2014

Dean’s List

Fall 2011 - Spring 2013

SPEED Alumni Award

Spring 2012

SPEED Scholars Award

Fall 2011 - Spring 2012

Dean’s Scholar

Fall 2011

Boy Scouts of America, Eagle Scout Rank

Summer 2009

Abstracts/Publications
1. S Carnahan BS, SC Koenig PhD, MA Sobieski RN CCP, E Schumer MD, G
Monreal PhD, Y Choi BS, B Meuris MEng, L Tompkins MEng, MS Slaughter MD,
GA Giridharan PhD. Efficacy of Subcutaneous ECG leads for Chronic
Counterpulsation Therapy, 2016. (submitted)
2. Schumer E, Monreal G, Carnahan S, Sobieski M, Slaughter M. Venovenous
Extracorporeal

Membrane

Oxygenation

for

Acute

Respiratory

Distress

Syndrome, KMA, 2014. (published)
3. Schumer E, Monreal G, Carnahan S, Sobieski M, Slaughter M. Outcomes for
Heart Transplantation in Patients Older than 64 at a Single-Center Institution,
KMA, 2014. (published)

Extracurricular Activities, Volunteer Experience, Leadership Activities
10-day Mission Trip to El Viejo Nicaragua
50

2014



Palmetto Medical Initiative, based in Charleston, SC, is an organization that
sends medical missionaries to underserved populations in Nicaragua and
Uganda. The medical care team that I served with provided a range of
services including the distribution of prescription drugs and providing patients
with education, reading glasses, wound care, physical therapy, and
Counseling. I secured over $3000 in private funding for this mission. I spent
most of my time on the trip distributing the pharmaceuticals and teaching our
patients how to take each individual medicine, with the help of an interpreter.

Member of Biomedical Engineering Society

2011-2014

Campus Crusaders for Christ (CRU)

2011-2014



Served as a worship leader during weekly meetings

Church Related Service


2001-present

I have identified myself as a Christian all of my life; consequently, I would feel
hypocritical if I didn’t try to serve others the way Christ serves his people.
Over the past few years, I have served people in the church and outside the
church through various organizations. I have served them by giving my most
valuable resources such as time and money to organizations such as
HOPEMOB, Eyes That See, Habitat for Humanity (H4H), Palmetto Medical
Initiative, etc. I have personally given my time to all of these different
organizations, but outside of that I can say I live a life of servitude to the
51

people around me by watching their kids for them, leading them in worship
during church, or feeding people that would otherwise go hungry.
Hobbies
2009-Present

Snowboarding/Water Skiing

Snow sports and water sports have been a passion of mine ever since I
was a little boy. However, seeing and riding the slopes of Kalispell, Montana is
what really sparked a life-long passion in me to snowboard. There is nothing
better than to fly down a mountain without another care in the world.

2007-Present

Playing Piano/Singing

Every person that has ever heard me play piano has told me I have a gift
for music. In fact, acceptance to the prestigious Governor’s School of the Arts is
primarily what allowed me to receive a Trustees Scholarship at the University of
Louisville for my undergraduate and graduate degrees. In addition, I have
accompanied for pay during various instrumental workshops and weddings. I
have also volunteered my services to many non-profit organizations.

2011-Present

Ultimate Frisbee

I have always had a strong body and when I came to college I found
Ultimate Frisbee to be a very good fit for me. It is a highly competitive, safe, noncontact, and fun sport, but the best feature is how it keeps me fit from all of the
running involved. Other Interests and Hobbies: Backpacking, camping, healthy
living, reading, medicine, soccer, landscaping, and traveling.
52

